NewsBenzingaJP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70 JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70 Benzinga 2026.10.15 13:14 (GMT+0) Open on Benzinga Other news T1 Energy Stock Plunges: What's Going On? Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT Nike CEO Says Co Aims To Double The Units Of Product Created In Under 14 Months By FY31